lung cancer

[Novartis AG] Novartis AG has announced the first published mature overall survival and updated overall response rate data following treatment with Tabrecta® in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14).

[Cellular & Molecular Biology Letters] Researchers observed for the first time that miR-33a-5p expression level was significantly decreased in pancreatic ductal adenocarcinoma tissues and cell lines.

[Cancer Discovery] Scientists examined 81 lung cancer patients under immune checkpoint blockade (ICB) treatment and found that patients with MET amplification were resistant to ICB and had a poor progress-free survival.

[Clinical Cancer Research] Researchers examined the ability of patient-derived organoids to predict clinical responses to targeted therapies in individual patients and to identify effective anti-cancer therapies for novel molecular targets.

[Clinical Oncology News] The FDA granted accelerated approval to amivantamab-vmjw for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

[Cell Death & Disease] Scientists clarified the role of KLHL38 in non-small cell lung cancer (NSCLC). KLHL38 expression was evaluated in tumor and adjacent normal tissues from 241 patients with NSCLC using immunohistochemistry and real-time PCR, and its association with clinicopathological parameters was analyzed.